Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05956665 · ClinicalTrials.gov registry record · NA
Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living
A NA study of Dementia and Quality of Life, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT05956665: Completed NA study of Dementia and Quality of Life, sponsored by Vanderbilt University.
NCT05956665 is a NA study of Dementia and Quality of Life that has completed, run by Vanderbilt University. The registered enrollment target is 18 participants, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05956665, a NA study of Dementia and Quality of Life, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This single-arm pilot study will evaluate the effects of an intervention to reduce exposure to unnecessary or potentially harmful medications among residents with dementia living in an assisted living facility. The goal of the intervention is to safely deprescribe medications (defined by dose reductions and stopped medications), based on a combination of clinical criteria and resident/surrogate preferences. The investigators will evaluate the effects of the intervention on the total number of medications deprescribed from enrollment at 30, 60, and 90 days along with resident/surrogate reports of quality of life at enrollment and 90 days.
Primary Outcome
The number of medications (including all prescribed and over-the-counter medications and both scheduled and as-needed medications) that have been deprescribed since enrollment. Deprescribed is defined as either stopping or reducing the dose/frequency of a medication.
Conditions Studied
Interventions
- BEHAVIORAL Shed-MEDS deprescribing intervention
Study Locations (2)
Tennessee
- Abe's Garden Community - Nashville
- NHC At The Trace - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
What the finished NCT05956665 record still lists
NCT05956665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which Shed-MEDS deprescribing intervention is the first listed.
NCT05956665 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05956665 about?
NCT05956665 is a clinical study titled "Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living". This single-arm pilot study will evaluate the effects of an intervention to reduce exposure to unnecessary or potentially harmful medications among residents with dementia living in an assisted living facility. The goal of the intervention is to safely deprescribe medications (defined by dose reduct...
What is the current status of trial NCT05956665?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2024-01-23. Estimated completion is 2025-08-15.
What conditions does trial NCT05956665 study?
This clinical trial studies the following conditions: Dementia, Quality of Life, Polypharmacy.
What interventions are being tested in trial NCT05956665?
The interventions under investigation include: Shed-MEDS deprescribing intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05956665?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05956665 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05956665's enrollment target sits among peer trials
18 190th of 199 higher than 9 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Caregiver as Navigator: Develop Skills Online (CAN-DO)
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Caregiver Bootcamp
RECRUITING · NA
-
Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision
RECRUITING · NA
-
Effect of Cognitive Empathy Training on Dementia Caregivers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI